The link between IFN-gamma and allograft arteriopathy: is the answer NO?

The Journal of Clinical Investigation
Richard N Mitchell, Andrew H Lichtman

Abstract

Vascularized organ transplants often fail because of smooth muscle cell migration and proliferation in the intima of graft arteries, leading to progressive lumenal narrowing and resultant ischemic damage. Graft arterial disease is caused by IFN-gamma secreted by alloreactive T cells. New evidence indicates that IFN-gamma dysregulates expression of the enzymes eNOS and iNOS in graft-infiltrating leukocytes. Dysregulated NO synthase expression occurs prior to and is causally linked to intimal smooth muscle cell accumulation.

References

Feb 24, 2001·Current Opinion in Cardiology·D BehrendtJ C Fang
Sep 24, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Melissa M Mazanet, Christopher C W Hughes
Oct 28, 2003·European Journal of Immunology·Nancy RodigGordon J Freeman
Jan 22, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Yinong WangGeorge Tellides
Feb 6, 2004·Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology·Richard N Mitchell
Mar 23, 2004·Annual Review of Immunology·Jaehyuk ChoiJordan S Pober
Jun 17, 2004·Circulation·Jean Davignon, Peter Ganz
Aug 3, 2004·The Journal of Clinical Investigation·Manfred BoehmElizabeth G Nabel
Sep 17, 2004·The Journal of Clinical Investigation·Kian Peng KohJordan S Pober

❮ Previous
Next ❯

Citations

Jun 12, 2010·Transplant International : Official Journal of the European Society for Organ Transplantation·Yang HengFeili Gong

❮ Previous
Next ❯

Methods Mentioned

BETA
xenografts
xenograft

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.